In cirrhosis, the development of ascites and the response to diuretics are determined by the RAAS (renin-angiotensin-aldosterone system) and renal sodium handling system. We hypothesized that SNPs (single nucleotide polymorphisms) affecting candidate genes in the RAAS and renal sodium handling pathway may influence initial diuretic responsiveness and affect clinical outcome in non-azotaemic cirrhotic patients with moderate ascites. We prospectively recruited 176 patients and 245 controls and determined their genetic polymorphisms for 24 SNPs of ten genes involved in the RAAS and renal sodium handling pathway. In cirrhotic patients with moderate ascites, multivariate analysis showed that diuretic unresponsiveness was predicted by a high basal plasma aldosterone level, by a high aldosterone/renin ratio and by specific risk genotypes of ACE (gene encoding angiotensin-converting enzyme), CYP11B2 (gene encoding aldosterone synthase) and ADDA (gene encoding α-adducin). This association between genetic polymorphisms and diuretic unresponsiveness was confirmed by an independent validation cohort. Notably, additive effects in relation to diuretic unresponsiveness were observed in cases where there was the simultaneous presence of the three risk genotypes. Among patients carrying any of the risk genotypes, more episodes of paracentesis and ascites-related readmission after 3 months of treatment, as well as a reduced 1-year survival rate, were observed. In addition to traditional predictors, our present study provides additional genetic and neurohormonal predictors that will help to identify diuretic non-responders among cirrhotic patients with moderate ascites. Among those carrying unfavourable risk genotypes, additional therapies, including paracentesis and albumin infusion, should be started as early as possible.
A B S T R A C T
In cirrhosis, the development of ascites and the response to diuretics are determined by the RAAS (renin-angiotensin-aldosterone system) and renal sodium handling system. We hypothesized that SNPs (single nucleotide polymorphisms) affecting candidate genes in the RAAS and renal sodium handling pathway may influence initial diuretic responsiveness and affect clinical outcome in non-azotaemic cirrhotic patients with moderate ascites. We prospectively recruited 176 patients and 245 controls and determined their genetic polymorphisms for 24 SNPs of ten genes involved in the RAAS and renal sodium handling pathway. In cirrhotic patients with moderate ascites, multivariate analysis showed that diuretic unresponsiveness was predicted by a high basal plasma aldosterone level, by a high aldosterone/renin ratio and by specific risk genotypes of ACE (gene encoding angiotensin-converting enzyme), CYP11B2 (gene encoding aldosterone synthase) and ADDA (gene encoding α-adducin). This association between genetic polymorphisms and diuretic unresponsiveness was confirmed by an independent validation cohort. Notably, additive effects in relation to diuretic unresponsiveness were observed in cases where there was the simultaneous presence of the three risk genotypes. Among patients carrying any of the risk genotypes, more episodes of paracentesis and ascites-related readmission after 3 months of treatment, as well as a reduced 1-year survival rate, were observed. In addition to traditional predictors, our present study provides additional genetic and neurohormonal predictors that will help to identify diuretic non-responders among cirrhotic patients with moderate ascites. Among those carrying unfavourable risk genotypes, additional therapies, including paracentesis and albumin infusion, should be started as early as possible.
INTRODUCTION
In cirrhosis, an increase in renin and the stimulation of angiotensin are major factors involved in renal sodium retention through the renal sodium handling system and subsequently ascites formation [1] [2] [3] . Angiotensinogen is produced by the liver, and renin can change angiotensinogen into AngI (angiotensin I). Next ACE (angiotensin-converting enzyme) is able to locally convert AngI into AngII (angiotensin II) [3] . In the kidney, AngII directly increases sodium re-absorption by the proximal tubules and indirectly increases distal tubules sodium re-absorption by stimulating aldosterone synthesis [3] .
A combined diuretic treatment, using spironolactone and furosemide which act through the RAAS (reninangiotensin-aldosterone system) and renal sodium handling system respectively, has been widely suggested as a useful treatment for moderate ascites in cirrhotic patients [4] [5] [6] . Spironolactone inhibits sodium re-absorption in the convoluted distal and collecting tubules by antagonizing the effect of aldosterone in those segments of the nephron, whereas furosemide inhibits chloride and sodium re-absorption in the ascending limb of the loop of Henle. However, the patient's response to the combined treatment is heterogeneous and a failure to control ascites ('non-responder') occurs at frequencies ranging from 24 to 50 % [6] [7] [8] . Several factors may influence the diuretic response, including low arterial blood pressure, abnormal blood volume distribution with effective hypovolaemia, cardiac dysfunction, overactivity of the sympathetic nervous system, increased neuropituitary release of vasopressin, and the effectiveness of the RAAS and renal sodium handling system [8] [9] [10] . Studies have suggested that genetic polymorphisms affect the haemodynamic response to β-adrenergic agonists and α 2 -adrenergic agonists and AT 1 (AngII type 1) receptor antagonists in cirrhotic patients [11] [12] [13] .
In addition to looking for genetic polymorphisms of the RAAS and the renal sodium handling system (Figure 1 ), we aimed to investigate the clinical and neurohormonal factors that may predict the initial diuretic response and delay clinical outcomes of responders and non-responders among cirrhotic patients with moderate ascites who were being treated with combined diuretics.
MATERIALS AND METHODS

Patients
From July 2005 to January 2009, we prospectively recruited 176 Han Chinese cirrhotic patients with ascites who presented at our hospital or who were already hospitalized. Non-azotaemic cirrhotic patients with moderate ascites between 20 and 80 years of age were included. The following criteria were required for inclusion in the study: moderate ascites (ascites causing moderate symmetrical distention of the abdomen) [4] , normal BUN (blood urea nitrogen; <25 mg/dl), serum creatinine (1.2 mg/dl), a PAC (plasma aldosterone concentration) >100 pg/ml (normal value, 30-100 pg/ml) and urinary Na + excretion >25 or <50 mmol/day. Patient with gastrointestinal bleeding, hepatic encephalopathy, infection, hepatocellular carcinoma and severe liver disease [serum bilirubin >10 mg/dl and INR (international normalized ratio) for prothrombin time >1.5], respiratory, cardiac or renal disease, and those treated with non-steroid anti-inflammatory, vasoactive or nephrotoxic drugs were excluded.
The cause of cirrhosis was alcoholic in 35 patients, HCV (hepatitis C virus)-associated in 45 cases, HbsAg (hepatitis B surface antigen)-associated in 61 cases, HCV and HBsAg-associated in 26 cases, and crytogenic in nine cases. The diagnosis of cirrhosis was based on liver biopsy results or on clinical, laboratory and ultrasonographic data. Ascites was diagnosed by clinical and abdominal ultrasonographic examinations. At the same time, 245 age-and sex-matched unrelated healthy controls, who visited our hospital for a health check-up and who had no clinical or biochemical evidence of liver, renal or cardiovascular disease, were recruited as a volunteer comparison group.
The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethical Committee of our Institutions. Written informed consent was obtained from all individuals.
Protocol
A step-wise increase in diuretics was given according to a previous study [7] . A washout period of 7 days was instituted first, and the diuretics taken before hospitalization were withheld. Diuretic treatment was started with 200 mg of spironolactone/day and 50 mg of furosemide/day (step 1). The dosages of the two drugs were increased if no response was observed to 400 mg of spironolactone/day and 100 mg of furosemide/day (step 2) and then to 400 mg of spironolactone/day and 150 mg of furosemide/day (step 3); each decision to increase the drug doses was taken at 3-day intervals [7] . The final therapeutic programme chosen was the minimum necessary to ensure no more than a 0.4-0.8 kg daily weight loss and to maintain a stable weight once free of ascites.
If an excessive diuretic response (mean body weight loss >500 g/day or >1000 g/day if peripheral oedema was present) or if any significant presumed complication arose, a reduction in the dosage or discontinuation of the medication was allowed. Diuretic responders and non-responders were defined at the end of 1 month of diuretic treatment. After the combined diuretic treatment, cirrhotic patients with moderate ascites who Figure 1 Overview of the candidate genes in the RAAS and renal sodium handling system investigated in the present study showed a decrease in body weight of <700 g every 3 days throughout the study and who re-accumulated ascites within 1 month after enrolment were defined as 'diuretic non-responders'. Conversely, 'diuretic responders' were defined as patients with a body weight loss >700 g every 3 days throughout the study and who did not have a re-accumulation of ascites within 1 month after enrolment. Patients who did not have an effective response to diuretics or who developed adverse effects due to the diuretics were then treated individually according to the guidelines for the treatment of cirrhotic ascitic patients [4, 5, 7] .
Clinical assessment
Before and during the study, body weight, abdominal circumference, UV (urine volume) and U Na V (urinary sodium excretion) were measured daily for each patient. Mean arterial pressure and heart rate were also determined regularly when a urine sample was collected. Biochemical tests were varied out every 3 days. A ChildPugh score and MELD (Model for End-Stage Liver Disease) score were then calculated using the formula described previously [11] .
For all cirrhotic patients with moderate ascites, plasma angiotensinogen, renin and aldosterone concentrations were measured to predict their contribution to the diuretic responsiveness, as described previously [9, 10] . To obtain an estimate of the AngII-independent rate of aldosterone production, the aldosterone/renin ratio was calculated for each patient [14] . Urine collection over 24 h was performed for measurement of Cl Cr (creatinine clearance) [15] . FE Na (fractional excretion of sodium) was calculated using the formula:
where U is urine, Cr is creatinine and P is plasma.
Genetic studies
We selected the most informative SNPs (single nucleotide polymorphisms) in candidate genes of the RAAS and renal sodium handling system that had available polymorphic information for a Han population by using Applied Biosystems SNP browser software version 3.0 [16] . Ideally, SNPs with a reported minor allele frequency of >10 % were selected. Genomic DNA was extracted from whole blood leucocytes using the QIAMP DNA Extraction kit (Qiagen). For the RAAS, we chose to investigate rs7080, rs1805090 and Met235Thr (M235T) (rs699) of AGT (the gene encoding angiotensinogen), rs34069565, rs5705 and rs11571117 of REN (the gene encoding renin), rs4544 and C − 344T of CYP11B2 (the gene encoding aldosterone synthase) and rs4298, I/D (insertion/deletion) (rs4341) and rs4364 of ACE. For the renal sodium handling pathway, we chose rs4961 of ADDA (the gene encoding α-adducin), rs2279365 and rs1426722 of SLC12A1 (the gene encoding the 
, rs1529927 and rs2099107 of SLC12A3 (the gene encoding the Na + /Cl − channel NCC), rs2228576 and rs3782726 of SCNN1A [the gene encoding the α-subunit of ENaC (epithelial Na + channel)], rs152745 and rs238547 of SCNN1B (the gene encoding the β-subunit of ENaC), and rs5733, rs4299163, rs5736 and rs5723 of SCNN1G (the gene encoding the γ -subunit of ENaC) ( Table 1) . The wild-type and risk genotypes of all the 24 SNPs described above were determined based on available public information and were assessed by the TaqMan allelic discrimination assay with a commercial kit (ABI), according to the manufacturer ' s instruction.
Validation cohort
To evaluate further the findings of our initial gene association study, an independent validation cohort was recruited to confirm the association between genetic polymorphisms and diuretic unresponsiveness. The independent cohort was recruited from on-going studies focusing on cirrhosis and ascites in different Departments of our hospital. A total of 170 independent cirrhotic patients with moderate ascites were identified and included in the genetic polymorphism analysis after the initial analysis to confirm the significant findings from our initial genetic studies.
Follow-up
The follow-up period started from the time of enrolment. After an initial clinical improvement, the patients were examined in the outpatient clinic on a weekly basis for the first month, and then monthly for the next 2 months. In addition to the initial diuretic response, delay outcomes, including a good diuretic response rate after 1 month of treatment, the mean dose of diuretics, the mean episode of ascites-related complications within 3 months of treatment and the 1-year survival rates, were calculated in cirrhotic patients with moderate ascites. All patients were followed until death, loss of follow-up or withdrawal from the study.
Data analysis
Results are reported as means (S.D.) or frequencies (percentage). A χ 2 test was used to check whether the genotype frequencies were consistent with the HardyWeinberg equilibrium. The risk genotypes that predicted diuretic non-responsiveness for either the RAAS or renal sodium handling system genes were coded '1' in the analysis, whereas the wild-type genotypes were coded '0'. When adding these risk genotypes together in a multiple genotype scale, cirrhotic patients with moderate ascites were divided further into different groups according to the number (0-6) of risk genotypes of the candidate genes in the RAAS, renal sodium handling pathway or both. In logistic regression, the group with the greatest case number was defined as reference group (see Figure 3) .
The distribution of genotypes between the groups was analysed using 3×2 or 2×2 χ 2 tests or Fisher's exact tests by SPSS 10.0.5 for Windows. Comparisons within each group were performed with a paired Student's t test for paired data or otherwise with the Wilcoxon signed rank test. Differences in initial diuretic response and delay outcomes between carriers of different risk genotypes were analysed by using one-way ANOVA. To evaluate the contributing effects of unfavourable factors on the diuretic response, significant univariate risk factors (presence of various risk genotypes, basal plasma aldosterone, renin and angiotensinogen levels, the aldosterone/renin ratio, and the plasma creatinine, bilirubin and albumin levels) were selected to enter into the multivariate regression analysis with an incrementally forward stepwise approach.
Survival curves were calculated by using the KaplanMeier method and compared using the log-rank test. Survival time (using the intention-to-treat methods) was calculated from the day a patient joined the study until their death or last day of follow-up. 
RESULTS
Responsiveness to combined diuretic treatment
A total of 158 out of the 176 cirrhotic patients with moderate ascites (90 %) received more than 1 month of combined diuretic treatment. Furthermore, 144 out of 176 (81 %) and 127 out of 176 (72 %) of them completed 3 months of treatment and 1-year of follow-up respectively. At step 1 of combined diuretic treatment (200 mg of spironolactone/day and 50 mg of furosemide/day), 29 out of 158 patients (18 %) lost their ascites. At step 2 (400 mg of spironolactone/day and 100 mg of furosemide/day), 50 out of 158 patients (32 %) lost their ascites. At step 3 (400 mg of spironolactone/day and 150 mg of furosemide/day), 42 out of 158 patients (27 %) lost their ascites. Notably, the severity of liver cirrhosis, the presence of peripheral oedema at inclusion, any previous history of ascites, the usage of diuretics to treat ascites and the grade of previous episodes of ascites before this episode of moderate ascites at inclusion were not different between diuretic responders and nonresponders. However, there were more adverse effects of diuretics, including hyperkalaemia and hypokalaemia, observed among the diuretic non-responders in the present study (Table 2) .
Genetic polymorphisms that negatively affect diuretic and natriuretic responses
We genotyped 24 SNPs that were located on the candidate genes of the RAAS and renal sodium handling pathway across the 176 cirrhotic patients with moderate ascites, together with 245 controls (Table 3, and Supplementary Tables S1 and S2 at Tables S1 and S2) . At this point, the cirrhotic patients with moderate ascites were divided into two groups on the basis of carrying either risk or wild-type genotypes of AGT,ACE,CYP11B2,ADDA and SCCN1G. Among the 24 SNPs that we studied, five SNPs [AGT (Met235Thr, rs699), ACE (I/D, rs4341), CYP11B2 (C − 344T), ADDA (Gly460Trp, rs4963) and SCCN1G (Leu649Leu, rs5723)] showed a statistically significant ability to predict diuretic unresponsiveness among cirrhotic patients with moderate ascites (Table 3) . Conversely, the distributions of the risk genotypes of the other 19 SNPs were not significantly different between diuretic responders 
(29 %)
and non-responders among the cirrhotic patients with moderate ascites (results not shown).
Basal clinical profiles in all cases
With the exception of plasma aldosterone, there was no difference in any of the basal parameters between the cirrhotic diuretic responders and non-responders (Table 4) . Nonetheless, plasma angiotensinogen levels were found to be significantly higher in cirrhotic patients carrying the AGT Met/Thr and Thr/Thr risk genotypes compared with those carrying the Met/Met wildtype genotype (Figure 2A ). Additionally, higher plasma aldosterone and renin levels ( Figure 2B ) were observed in cirrhotic patients carrying the ACE ID and DD risk genotypes than those carrying II wild-type genotypes. Notably, the plasma aldosterone and renin concentrations were not significantly different between the cirrhotic ascitic patients with different the CYP11B2 genotypes ( Figure 2C ). In contrast, the plasma aldosterone/renin ratio was markedly higher in the CYP11B2 CT and TT risk genotypes than those carrying the CC wild-type genotype among cirrhotic patients with moderate ascites ( Figure 2D ).
Synergistic effects of various risk genotypes on the activity of the RAAS and renal sodium handling system
In cirrhotic patients with moderate ascites, a threshold effect was observed in that the risk of diuretic unresponsiveness in cases without any risk genotypes of candidate genes of the RAAS was 0.12 times greater [95 % CI (confidence interval), 0.3-0.9], with one risk genotype the risk was 0.89 times greater (95 % CI, 0.7-1.8) and with three genotypes the risk was 2.53 times greater (95 % CI, 0.9-2.4) compared with individuals with two risk genotypes of the RAAS genes (P value for trend = 0.04; Figure 3A ). For the renal sodium handling system candidate genes, the risk of diuretic unresponsiveness in cirrhotic ascitic patients without any risk genotypes was 0.7 times lower (95 % CI, 0.3-1.5) than among those with one risk genotype, whereas, for those with two risk genotypes, it was 1.9 times higher (95 % CI, 0.9-5.4) (P value for trend = 0.065; Figure 3B ).
When the combined effect of all risk genotypes for both the RAAS and renal sodium handling system candidate genes were considered, the risk of diuretic unresponsiveness in those with no risk genotypes was 0.3 times greater (95 % CI, 0.2-3.1), with one risk genotype was 0.5 times greater (95 % CI, 0.3-2.2) and with two risk genotypes was 0.9 times greater (95 % CI, 0.9-2.8) than those with three risk genotypes. Furthermore, the risk of diuretic unresponsiveness in those with four risk genotypes was 1.8 times greater (95 % CI, 1.1-4.1) and with five risk genotypes was 2.4 times greater (95 % CI, 0.7-2.6) than those with three risk genotypes ( Figure 3C ).
Factors that predict diuretic unresponsiveness
Univariate analysis showed that a high basal plasma aldosterone level, a high aldosterone/renin ratio, and carrying the AGT (Met/Thr, rs699), ACE (I/D, rs4341), CYP11B2 (C − 344T), ADDA (Gly460Trp) and SCCN1G (C/G, rs5723) risk genotypes were Figure 2 Effect of the various risk genotypes of the candidate genes in the RAAS and (A) plasma angiotensinogen, (B and C) plasma aldosterone and renin levels, and (D) the plasma aldosterone/renin ratio * P < 0.01 and * * P < 0.001 compared with the patients carrying the risk genotypes.
significantly associated with diuretic unresponsiveness (Table 5) . However, multivariate analysis showed that only a high basal plasma aldosterone level, a high aldosterone/renin ratio, and carrying the ACE (I/D, rs4341), CYP11B2 (C − 344T) and ADDA (Gly460Trp) risk genotypes were independently associated with diuretic unresponsiveness.
Confirmation of the significant genetic associations using a validation cohort
Furthermore, 105 diuretic responders and 65 nonresponders were observed among a validation cohort of cirrhotic patients with moderate ascites. As shown in Supplementary Table S3 (at http://www.clinsci.org/cs/121/ cs1210509add.htm), the age-and sex-matched validation cohort shared many common characteristics with our studied cirrhotic patients. We then chose the three SNPs that had shown evidence of association with diuretic unresponsiveness among our initial cirrhotic patients. The members of the independent validation cohort were then genotyped for these SNPs to confirm the observed association. Notably, it was found that the patients from the independent validation cohort carrying the risk genotypes of ACE (I/D, rs4341), CYP11B2 (C − 344T) and ADDA (Gly460Trp) showed a significant association with diuretic unresponsiveness (Table 6 ).
Effects of genetic factors on delaying clinical outcomes in cirrhotic patients receiving diuretic treatment
After 1 month of combined diuretic treatment in both the diuretic responders and non-responders, renal function (Cl Cr ) was not significantly different from basal (84 + − 21 and 78 + − 25 ml/min at baseline and after 1 month in responders respectively, and 81 + − 22 and 74 + − 19 ml/min at baseline and after 1 month in nonresponders respectively). Although deterioration in renal function was observed after 3 months of combined diuretic treatment, the degree of the decrease was similar between diuretic responders and non-responders in our present study [84 + − 21 and 73 + − 18 ml/min at baseline and after 3 months in responders respectively (13 + − 1.0 % decrease from baseline), and 81 + − 22 and 69 + − 16 ml/min at baseline and after 1 month in non-responders respectively (14 + − 2.1 % decrease from baseline)].
Less improvement in daily UV (diuretic effect) and urinary sodium excretion (U Na V and FE Na , natriuretic effect) after 1 month of use of combined diuretics were observed in cirrhotic patients who carried any of the ACE (I/D), CYP11B2 (C − 344T) and ADDA (Gly460Trp) risk genotypes (Figure 4) . The probability of a good diuretic response after 1 month of treatment in cases carrying any of the risk genotypes of these candidate genes (ACE,CYP11B2 and ADDA) was significantly lower than those without any of the risk genotypes ( Figure 5A ).
In comparison with cirrhotic ascitic patients without the ACE (I/D), CYP11B2 (C − 344T) or ADDA (Gly460Trp) risk genotypes, after 3 months of combined diuretic treatment higher mean doses of spironolactone and furosemide (as well as more occurrences of paracentesis) were needed to control ascites in those carrying any of the above risk genotypes (Table 7) . Meanwhile, cirrhotic ascitic patients carrying any of the above risk genotypes had more episodes of ascites-related admissions than patients not carrying any of the risk genotypes; furthermore, these patients also had a lower 1-year survival compared with patients without any of the risk genotypes ( Figure 5B ).
DISCUSSION
In the present study, we observed that there was a significant association of diuretic unresponsiveness with common risk variants of candidate genes in the RAAS (ACE and CYP11B2) and renal sodium handling pathway (ADDA) in cirrhotic patients with moderate ascites. We also found evidence of an interaction between the risk variants of the above candidate genes, and a high basal aldosterone level and a high aldosterone/renin ratio when predicting diuretic unresponsiveness. In comparison with patients without any risk genotypes, the results of the present study suggested that patients carrying of any the ACE (I/D), CYP11B2 (C − 344T) or ADDA (Gly460Trp) risk genotypes had a poorer clinical outcomes after 3 months of treatment and had a lower 1-year survival. In previous studies, it was shown that Met235Thr is a common variant at codon 235 of the ATG gene; specifically, there is a methionine to threonine amino acid substitution and this results in an increase in plasma angiotensinogen levels [17, 18] . Clinically, the Thr/Thr risk genotype of the AGT gene has been linked to a poor response to antihypertensive drugs [17, 18] . Similarly, in the present study, we found that cirrhotic patients with moderate ascites who carry the AGT (Met/Thr and Thr/Thr) risk genotypes had an association with an increased plasma angiotensinogen level and greater diuretic unresponsiveness.
The ACE gene I/D polymorphism results in three genotypes (DD and II homozygotes, and ID heterozygotes) [19] . However, conventional genotyping methods for detecting the ACE I/D polymorphism, which involves PCR-gel electrophoresis, shows a high mistyping rate and is laborious and time-consuming [20] . A recent study has suggested that rs4341 genotyping, which is closely linked to the ACE I/D polymorphism, by the TaqMan allelic discrimination method is a fast and convenient alternative method for direct I/D genotyping [20] . On the basis of that finding, we have determined the polymorphism for this SNP (rs4341) using the TaqMan allelic discrimination method to discriminate different ACE genotypes (II, ID and DD). In patients with heart failure carrying the ACE DD risk genotype, it has been found that there is an association with diuretic unresponsiveness due to increased ACE activity and more local AngII/aldosterone production [19, 21] . Our present study revealed that, among cirrhotic patients with moderate ascites who carry the ACE ID/DD risk genotype, there was less natriuresis and diuresis; this results in a need for a higher mean diuretic dose, more episodes of paracentesis and a higher ascites-related readmission compared with similar patients who carried the ACE II wild-type genotype.
Aldosterone is one of the main effectors of the RAAS, which promotes the retention of sodium and activates the sympathetic nervous system. The synthesis of aldosterone is regulated by aldosterone synthase, which is regulated by the CYP11B2 gene and AngII [22] . The − 344 T/C polymorphism in the CYP11B2 promoter region results in higher aldosterone production. Patients with the TT risk genotype have high AngIIindependent aldosterone production [23] . In our present study, we calculated the aldosterone/renin ratio in order to determine the AngII-independent secretion of aldosterone [14] . Thus in the present study it is reasonable that, when carrying the CYP11B2 risk genotype, a high basal aldosterone level and a high aldosterone/renin ratio were independent predictors for diuretic unresponsiveness in cirrhotic patients with moderate ascites.
Adducin is a heterodimeric protein that consists of α-, β-and γ -subunits to regulate renal sodium handling [24] . ADDA is involved in ion transport and signal transduction [24] . It has been shown that SNPs of ADDA, a substitution of tryptophan for glycine at residue 460 (Gly460Trp) affects Na + /K + -ATPase activity at the basolateral tubular membrane and an increase in proximal tubular Na + re-absorption [25] . Furthermore, the ENaC is composed of three subunits, α-, β-and γ -subunits, which are encoded by SCNN1A, SCNN1B and SCNN1G respectively [25] . Evidence has been suggested that the polymorphism (rs5723) in SCNN1G, a C to G exchange, is significantly associated with a poor response to diuretics [26] . Our present study showed that a lower diuretic response was found in cirrhotic patients carrying either the ADDA or SCNN1G risk genotype. Moreover, a higher mean dosage of spironolactone and furosemide, an increased mean number of paracentesis procedures and an increase in ascites-related readmission were (B) Survival rates at 1 year (compared by log-rank test) between cirrhotic patients carrying of any the risk genotypes compared with those not carrying any risk genotypes.
* P < 0.01 and * * P < 0.001 compared with cirrhotic patients not carrying the risk genotypes. It had been reported that polymorphisms of SLC12A1 and SCL12A3 lead to a high activity of the Na + -K + pump and, hence, increased renal tubular sodium re-absorption, which increases the risk of diuretic unresponsiveness [26] . However, a lack of any effects of the SLC12A1 and SLC12A3 polymorphisms on diuretic responsiveness was observed in our present study. These results might be attributable to inter-diseases variations in the role of SLC12A1 and SLC12A3 on diuretic responses.
In the present study, the limited sample size is one concern and it is not possible to rule out the possibility of false-positive results in relation to the associations between various genetic polymorphisms and diuretic unresponsiveness. To alleviate this concern to some degree, the association results were successfully validated using an independent cohort. Nonetheless, further studies involving larger numbers of cirrhotic patients with moderate ascites are needed. Such a genetic analysis will help to confirm the genotypes of the genes relevant to the control of sodium handling that can be used to identify diuretic non-responders. This will allow the therapy chosen to be adapted to the individual patient at an early stage. However, at present, such genotyping is not regularly accessible to general clinicians and this will limit the initial usefulness of our present findings. In addition, the results of our present study suggest that having one or more risk genotypes, namely ACE (I/D), CYP11B2 (C − 344T) or ADDA (Gly460Trp), does not necessarily mean that the patient will definitely develop diuretic unresponsiveness. In other words, haemodynamic and neurohormonal abnormalities interact with the presence of risk genotypes and these result in an increase in the overall probability that cirrhotic patients with moderate ascites will show diuretic unresponsiveness.
Thus, from a practical point of view, ascites should still be treated according to the clinical manifestations, rather than the patient's genetic profile. Nonetheless, genetic profiling could have potential benefits when managing cirrhotic patients with moderate ascites because it will help to identify patients who show a faster evolution of the disease and are thus potentially at risk of surviving for a shorter time. Notably, our present study found that cirrhotic patients with moderate ascites carrying the risk genotypes have more episodes of ascites-related admissions (faster evolution of the disease) and poor 1-year survival (shorter survival) than patients not carrying any of the risk genotypes. In conclusion, if genetic testing is available, identification of the at-risk genes, especially if there are several of them, is important and if the patient does not respond to standard diuretic treatment, their presence should urge the clinician towards a second line of treatment instead of an escalation in the diuretic dose. In other words, an early multi-modality strategy and liver transplantation might be worthy of consideration in such cases.
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